FORM 3
        
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

 OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                       
1. Name and Address of Reporting Person * Devall Christopher Franklin 2. Date of Event Requiring Statement (MM/DD/YYYY)
1/1/2023 

 3. Issuer Name and Ticker or Trading Symbol Dominari Holdings Inc. [DOMH]
(Last)        (First)        (Middle)
ONE ROCKEFELLER PLAZA,, 11TH FLOOR		 4. Relationship of Reporting Person(s) to Issuer (Check all applicable)_____ Director                          _____ 10% Owner
___X___ Officer (give title below)        _____ Other (specify below)
Chief Operating Officer /
(Street)
NEW YORK, NY 10020      
(City)              (State)              (Zip)
 5. If Amendment, Date Original Filed(MM/DD/YYYY)
 

 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)		 2. Amount of Securities Beneficially Owned
(Instr. 4)		 3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)		 4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Common Stock  13835 (1) D   

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 4)		 2. Date Exercisable and Expiration Date
(MM/DD/YYYY)		 3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)		 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)		 6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares

Explanation of Responses:
(1)  On December 16, 2022, the reporting person purchased 3,000 shares of common stock in the public market at an average price of $3.71 per share. On December 19, 2022, the reporting person purchased 1,389 shares of common stock in the public market at $3.599 per share. On December 21, 2022, the reporting person purchased 1,378 shares of common stock in the public market at $3.6599 per share. On July 1, 2022, the reporting person was granted 8,068 shares of restricted stock pursuant to the Company's 2014 Equity Incentive Plan which fully vested on January 1, 2023.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Devall Christopher Franklin
ONE ROCKEFELLER PLAZA,
11TH FLOOR
NEW YORK, NY 10020

Chief Operating Officer

Signatures
/s/ Christopher Devall 1/6/2023
**Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Alkido Pharma (NASDAQ:AIKI)
Historical Stock Chart
From Feb 2023 to Mar 2023 Click Here for more Alkido Pharma Charts.
Alkido Pharma (NASDAQ:AIKI)
Historical Stock Chart
From Mar 2022 to Mar 2023 Click Here for more Alkido Pharma Charts.